In vitro anti-tumour activity of anti-CD80 and anti-CD86 immunotoxins containing type 1 ribosome-inactivating proteins

被引:64
作者
Bolognesi, A
Polito, L
Tazzari, PL
Lemoli, RM
Lubelli, C
Fogli, M
Boon, L
De Boer, M
Stirpe, F
机构
[1] Univ Bologna, Dipartimento Patol Sperimentale, I-40126 Bologna, Italy
[2] Univ Bologna, Ist Ematol & Oncol Med L&A Seragnoli, Bologna, Italy
[3] Policlin S Orsola, Serv Immunoematol & Trasfus, I-40138 Bologna, Italy
[4] Tanox Pharma BV, Amsterdam, Netherlands
关键词
immunotoxin; ribosome-inactivating proteins; CD80; CD86; Hodgkin's disease;
D O I
10.1046/j.1365-2141.2000.02193.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Immunotoxins specific for the CD80 and CD86 antigens were prepared by linking three type 1 ribosome-inactivating proteins (RIPs), namely bouganin, gelonin and saporin-S6, to the monoclonal antibodies M24 (anti-CD80) and 1G10 (anti-CD86). These immunotoxins showed a specific cytotoxicity for the CD80/CD86-expressing cell lines Raji and L428. The immunotoxins inhibited protein synthesis by target cells with IC(50)s (concentration causing 50% inhibition) ranging from 0.25 to 192 pmol/l as RIPs. The anti-CD80 immunotoxins appeared 1-2 log more toxic for target cells than the anti-CD86 ones, Immunotoxins containing saporin and bouganin induced apoptosis of target cells. The toxicity for bone marrow haemopoietic progenitors of these conjugates was also evaluated. Bouganin and related immunotoxins at concentrations up to 100 nmol/l did not significantly affect the recovery of committed progenitors or of more primitive cells. The saporin-containing immunotoxins at concentrations greater than or equal to 1 nmol/l showed some toxicity on colony-forming unit cells (CFU-C). The expression of the CD80 and CD86 molecules is prevalently restricted to antigen-presenting cells and is also strong on Hodgkin and Reed-Sternberg cells in Hodgkin's disease. Present results suggest that immunotoxins targeting type 1 ribosome-inactivating proteins to these antigens could be considered and further studied for the therapy of Hodgkin's disease or other CD80/CD86-expressing tumours.
引用
收藏
页码:351 / 361
页数:11
相关论文
共 31 条
[11]   RESPONSE OF REFRACTORY HODGKINS-DISEASE TO MONOCLONAL ANTI-CD30 IMMUNOTOXIN [J].
FALINI, B ;
BOLOGNESI, A ;
FLENGHI, L ;
TAZZARI, PL ;
BROE, MK ;
STEIN, H ;
DURKOP, H ;
AVERSA, F ;
CORNELI, P ;
PIZZOLO, G ;
BARBABIETOLA, G ;
SABATTINI, E ;
PILERI, S ;
MARTELLI, MF ;
STIRPE, F .
LANCET, 1992, 339 (8803) :1195-1196
[12]   Selective expansion of normal haemopoietic progenitors from chronic myelogenous leukaemia marrow [J].
Fogli, M ;
Amabile, M ;
Martinelli, G ;
Fortuna, A ;
Rondelli, D ;
Ratta, M ;
Curti, A ;
Tura, S ;
Lemoli, RM .
BRITISH JOURNAL OF HAEMATOLOGY, 1998, 101 (01) :119-129
[13]   CLONING OF B7-2 - A CTLA-4 COUNTER-RECEPTOR THAT COSTIMULATES HUMAN T-CELL PROLIFERATION [J].
FREEMAN, GJ ;
GRIBBEN, JG ;
BOUSSIOTIS, VA ;
NG, JW ;
RESTIVO, VA ;
LOMBARD, LA ;
GRAY, GS ;
NADLER, LM .
SCIENCE, 1993, 262 (5135) :909-911
[14]   Pathophysiology of Hodgkin's disease: Functional and molecular aspects [J].
Gruss, HJ ;
Kadin, ME .
BAILLIERES CLINICAL HAEMATOLOGY, 1996, 9 (03) :417-446
[15]   Role of caspases in immunotoxin-induced apoptosis of cancer cells [J].
Keppler-Hafkemeyer, A ;
Brinkmann, U ;
Pastan, I .
BIOCHEMISTRY, 1998, 37 (48) :16934-16942
[16]   CTLA4-Ig and anti-CD4O ligand prevent renal allograft rejection in primates [J].
Kirk, AD ;
Harlan, DM ;
Armstrong, NN ;
Davis, TA ;
Dong, YC ;
Gray, GS ;
Hong, XN ;
Thomas, D ;
Fechner, JH ;
Knechtle, SJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (16) :8789-8794
[17]   Involvement of both caspase-like proteases and serine proteases in apoptotic cell death induced by ricin, modeccin, diphtheria toxin, and Pseudomonas toxin [J].
Komatsu, N ;
Oda, T ;
Muramatsu, T .
JOURNAL OF BIOCHEMISTRY, 1998, 124 (05) :1038-1044
[18]   Immunotoxins for targeted cancer therapy [J].
Kreitman, RJ ;
Pastan, I .
ADVANCED DRUG DELIVERY REVIEWS, 1998, 31 (1-2) :53-88
[19]   Cycling status of CD34(+) cells mobilized into peripheral blood of healthy donors by recombinant human granulocyte colony-stimulating factor [J].
Lemoli, RM ;
Tafuri, A ;
Fortuna, A ;
Petrucci, MT ;
Ricciardi, MR ;
Catani, L ;
Rondelli, D ;
Fogli, M ;
Leopardi, G ;
Ariola, C ;
Tura, S .
BLOOD, 1997, 89 (04) :1189-1196
[20]   CD28/B7 system of T cell costimulation [J].
Lenschow, DJ ;
Walunas, TL ;
Bluestone, JA .
ANNUAL REVIEW OF IMMUNOLOGY, 1996, 14 :233-258